Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
28.41
-0.76 (-2.61%)
Nov 2, 2026, 4:00 PM EST - Market closed
Immunovant Employees
Immunovant had 315 employees as of March 31, 2026. The number of employees decreased by 47 or 12.98% compared to the previous year. That makes Immunovant the 23,487th largest employer in the world and 3,029th in the United States.
Employees
315
Change (1Y)
-47
Growth (1Y)
-12.98%
Revenue / Employee
n/a
Profits / Employee
-$1,708,625
Market Cap
5.87B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 315 | -47 | -12.98% |
| Mar 31, 2025 | 362 | 155 | 74.88% |
| Mar 31, 2024 | 207 | 43 | 26.22% |
| Mar 31, 2023 | 164 | 40 | 32.26% |
| Mar 31, 2022 | 124 | 56 | 82.35% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,480 |
| Mirum Pharmaceuticals | 433 |
| Rhythm Pharmaceuticals | 414 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
| Oruka Therapeutics | 68 |
IMVT News
- 12 days ago - Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 - GlobeNewsWire
- 22 days ago - IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law - Business Wire
- 25 days ago - Immunovant down after Argenx study fails in Sjogren’s disease - TheFly
- 5 weeks ago - Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT) - PRNewsWire
- 5 weeks ago - Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback - TheFly
- 5 weeks ago - Immunovant announces IMVT-1402 study did not achieve statistical significance - TheFly
- 5 weeks ago - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus - GlobeNewsWire
- 5 weeks ago - Immunovant Slides: Corporate presentation - Filings